

# **Risk of Kaposi Sarcoma in HIV-Positive Adults on ART: a Global Analysis**

<sup>1</sup>University of Bern, Switzerland, <sup>2</sup>University of Witwatersrand, South Africa, <sup>3</sup>Kaohsiung Medical University, Taiwan, <sup>4</sup>Fundacion Huesped, Argentina, <sup>5</sup>Northwestern University, USA.

## Background

Kaposi sarcoma (KS) is one of the most common tumors in HIVpositive persons. Epidemic KS is caused by human herpesvirus 8 (HHV-8) infection and HIV-related immunosuppression. The prevalence of HIV and HHV-8 varies between different geographic regions. HHV-8 prevalence in the general population is much higher in sub-Saharan Africa than in Europe and North America, for example.

# **Objectives**

- To compare KS incidence rates in HIV-positive adults on combination antiretroviral therapy (ART) globally
- To examine risk factors for developing KS in HIV-positive adults on ART

## **Methods**

- We analyzed data from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
- We included HIV-positive adults (≥16 years) who initiated ART after enrollment into cohort from 1996 onwards.
- We compared the risk of incident KS after starting ART between regions using flexible parametric survival models with region-specific baseline hazards, adjusted for age, sex and its interaction with region, time-updated CD4 cell counts and year of ART start.
- We excluded the Asia-Pacific and Australia from multivariable analyses due to the small sample size.
- We present hazard ratios (HR) and 95% confidence intervals (CI) by time since ART start and at 2 years after ART start.


Table: C

Adults ( Median [years] Men MSM

Median count [c

ART, combination antiretroviral therapy; KS, Kaposi sarcoma; MSM, men who have sex with men, N, number, NR, not reported. Medians are presented with interquartile ranges.

# Figure: Adjusted HR and 95% CI for the risk of developing KS in different regions.



Funding: Supported by the National Institute Of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), of the U.S. National Institutes of Health (NIH) under Award Number Southern Africa: U01AI069924, Asia-Pacific: U01AI069907, Caribbean, Central, and South America: U01AI069923, NA-ACCORD: U01-AI069918 and the IeDEA Network Coordinating Center at Vanderbilt: U01A1096186. The COHERE study group has received unrestricted funding from: Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS), France; HIV Monitoring Foundation, the Netherlands; and the Augustinus Foundation, Denmark. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694. list of the funders of the participating cohorts can be found on the Regional Coordinating Centre websites at http://www.cphiv.dk/COHERE/tabid/295/Default.aspx and http://etudes.isped.u-bordeaux2.fr/cohere." The full acknowledgement section for COHERE in EuroCoord is shown next to the poster

Eliane Rohner<sup>1</sup>, Julia Bohlius<sup>1</sup>, Lukas Bütikofer<sup>1</sup>, Mhairi Maskew<sup>2</sup>, Yi-Ming A. Chen<sup>3</sup>, Valeria Fink<sup>4</sup>, Chad Achenbach<sup>5</sup>, Matthias Egger<sup>1</sup> for the International Epidemiologic Databases to Evaluate AIDS (leDEA) and the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.

	Asia- Pacific	Australia	Southern Africa	Latin America	North America	Europe
(N)	2,649	344	172,863	8,599	16,756	160,178
age	36	42	35	36	40	37
	(31-43)	(35-48)	(30-42)	(30-43)	(34-46)	(31-45)
	69%	92%	37%	73%	75%	72%
	23%	67%	NR	42%	50%	39%
CD4 cell	137	283	141	165	233	250
cells/µl]	(43-234)	(210-398)	(72-210)	(61-273)	(93-378)	(127-369)

**Project working group:** Michael Vinikoor, Kathryn Stinson, Daniela Garone, Cleophas Chimbetete, Mhairi Maskew, Hans Prozesky, Helena Rabie, Mary-Ann Davies, Janet Giddy, Annette Sohn, Arthur Chen, Awachana Jiamsakul, Nicolas Durier, Chuenkamol Sethaputra, Kathy Petoumenos, Valeria Fink, Cathrine McGowan, Pedro Cahn, Beatriz Grinsztein, Gina Perez, Karu Jayathilake, Gypsyamber D'Souza, Richard Moore, Michael Silverberg, M John Gill, Sonia Napravnik, Chad Achenbach, James Goedert, Mari Kitahata, Pragna Patel, Rob Dubrow, Gary Clifford, Jonathan Sterne, Julia Bohlius, Eliane Rohner, Lukas Bütikofer, Marcel Zwahlen, Margaret May, Maria Campbell, Matthias Egger, Sylvia Franceschi, Kurt Schmidlin, Robert Zangerle, Vassilios Paparizos, Vincent Le Moing, Fabrice Bonnet, Annelies Verbon, Frank Post, Gerd Fätkenheuer, Julia Del Amo, Fernando Dronda, Niels Obel, Amanda Mocroft, Sophie Grabar, Andrea Antinori, Eugenia Quiros-Roldan, Cristina Mussini, Jordi Casabona, José Miró, Laurence Meyer, Vincenzo Spagnuolo, Barbara Hasse, Stéphane De Wit, Deborah Konopnicki, Caroline Sabin, Bernardino Roca.

### sults

# Limitations

- KS diagnoses not in all regions histologically confirmed

# **Conclusions**

Women in Southern Africa had a higher KS risk than women in Europe which was not explained by HIV-related risk factors. In men KS risk was similar across regions after adjusting for HIV-related risk factors. This pattern likely reflects different HHV-8 risk profiles: while men were at high risk of HHV-8 infection in most regions (MSM or resident in HHV-8 endemic regions) the main risk factor for HHV-8 infection in women was residence in HHV-8 endemic regions.



Abstract #618

We included 361,389 HIV-positive adults from the Asia-Pacific, Australia, Southern Africa, Latin America, North America, and Europe (Table).

Over 1.4 million person-years (pys) 2,725 adults developed KS for an overall incidence rate of 196/100,000 pys (95%CI 188-203).

After 2 years on ART KS incidence was higher in women from Southern Africa than in European women (adjusted HR 2.2, 95%CI 1.8-2.8) and similar to European women in women from Latin and North America.

In men crude KS risk after 2 years on ART was higher in North America compared to Europe (HR 1.5, 95%CI 1.2-1.9), in multivariable analyses this risk declined to HR 1.1 (95%CI 0.9-1.4). The change was mainly explained by adjusting for time-updated CD4 cell counts. KS risk was similar in men from other regions (Figure).

Migration data were not available for all regions and hence not considered in the analyses

No data on HHV-8 status of included adults available

**Contact:** Eliane Rohner Institute of Social and Preventive Medicine, University of Bern, Switzerland; e-mail: eliane.rohner@ispm.unibe.ch